---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-009136"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T05:52:45.323179+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Odyssey Health closes asset sale of brain illness drug candidates to Oragenics for $1M cash and 8M preferred shares

## Summary
- Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.
- Received $1M in cash plus 8M shares of convertible Series F Preferred Stock from Oragenics.
- Closing conditions included shareholder approvals from both Odyssey and Oragenics; no material adverse change required.
- Odyssey previously disclosed the Purchase Agreement in an October 5, 2023 8-K.

## SEC filing metadata
- accession: 0001683168-23-009136
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316823009136/0001683168-23-009136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316823009136/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-009136
- JSON: https://secwatch.observer/filing/0001683168-23-009136.json
- Plain text: https://secwatch.observer/filing/0001683168-23-009136.txt

## Key facts
- M&A Transactions
  Odyssey Health, Inc. completed a disposition involving Oragenics, Inc. for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (closed 2023-12-28).
  - Action: disposition
  - Counterparty: Oragenics, Inc.
  - Consideration: $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock
  - Closing: 2023-12-28
  source text: to a segment of Odyssey’s business focused on developing medical products that treat brain related illnesses and diseases (the “ Purchased Assets ”) to Oragenics in exchange for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (“ Series F Preferred Stock ”), on and subject to the terms and conditions set forth therein
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626644/000168316823009136/0001683168-23-009136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.